Having trouble accessing articles? Reset your cache.

Pfizer ends Sutent study for prostate cancer

Pfizer Inc. (NYSE:PFE) discontinued a Phase III trial of Sutent sunitinib to treat advanced castration-resistant prostate cancer (CRPC) and provided an update on

Read the full 237 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE